AstraZeneca PLC
| NYSE: AZN |
| Healthcare / Drug Manufacturers / United Kingdom |
| 64.49 | +1.35 | +2.14% | Vol 5.58M | 1Y Perf 14.36% |
| May 16th, 2022 16:00 DELAYED |
| BID | 63.80 | ASK | 64.51 | ||
| Open | 63.35 | Previous Close | 64.49 | ||
| Pre-Market | - | After-Market | 64.31 | ||
| - - | -0.19 -0.29% |
| Target Price | 74.25 | Analyst Rating | Strong Buy 1.40 | |
| Potential % | 15.13 | Finscreener Ranking | ★★ 46.46 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★ 41.40 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★+ 40.15 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | ★★★+ 48.38 | |
| Price Range Ratio 52W % | 60.10 | Earnings Rating | Strong Buy | |
| Market Cap | 199.85B | Earnings Date | 29th Apr 2022 | |
| Alpha | 0.01 | Standard Deviation | 0.06 | |
| Beta | 0.45 |
Today's Price Range 63.3564.80 | 52W Range 53.6371.70 | 5 Year PE Ratio Range 19.20126.10 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 1.34% | ||
| 1 Month | -6.60% | ||
| 3 Months | 5.74% | ||
| 6 Months | 11.71% | ||
| 1 Year | 14.36% | ||
| 3 Years | 70.70% | ||
| 5 Years | 88.73% | ||
| 10 Years | 263.11% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 5.41 | |||
ROE last 12 Months | -4.25 | |||
ROA (5Y Avg) | 1.07 | |||
ROA last 12 Months | -1.32 | |||
ROC (5Y Avg) | 8.36 | |||
ROC last 12 Months | -0.09 | |||
Return on invested Capital Q | 0.89 | |||
Return on invested Capital Y | -0.13 | |||
Assets Turnover | 0.50 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -185.70 | ||||
| 5.38 | ||||
| 5.28 | ||||
| 25.90 | ||||
| -20.80 | ||||
| 2.44 | ||||
| -7.86 | ||||
| 11.73 | ||||
| 219.79B | ||||
| Forward PE | 17.10 | |||
| PEG | -11.46 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.30 | ||||
| 1.00 | ||||
| 0.44 | ||||
| 0.86 | ||||
| 0.00 | ||||
| Leverage Ratio | 2.90 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 66.10 | ||||
| 0.00 | ||||
| 16.90 | ||||
| 6.90 | ||||
| -2.48 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 37.87B | ||||
| 12.22 | ||||
| 16.49 | ||||
| 9.31 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.99 | ||||
| 1.93 | ||||
| 0.24 | ||||
| 0.11 | ||||
| Payout ratio | 93.00 |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2022 | 0.86 | 0.95 | 10.47 |
| Q04 2021 | 0.77 | 0.84 | 9.09 |
| Q03 2021 | 0.63 | 0.54 | -14.29 |
| Q02 2021 | 0.45 | 0.45 | 0.00 |
| Q01 2021 | 0.71 | 0.81 | 14.08 |
| Q04 2020 | 0.53 | 0.54 | 1.89 |
| Q03 2020 | 0.49 | 0.47 | -4.08 |
| Q02 2020 | 0.44 | 0.48 | 9.09 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2022 QR | 0.78 | 13.04 | Positive |
| 9/2022 QR | 0.81 | 12.50 | Positive |
| 12/2022 FY | 3.34 | 2.77 | Positive |
| 12/2023 FY | 3.77 | -1.31 | Negative |
| Next Report Date | - |
| Estimated EPS Next Report | 0.84 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | 16.20 |
| Volume Overview | |
|---|---|
| Volume | 5.58M |
| Shares Outstanding | 3.10M |
| Shares Float | 3.10B |
| Trades Count | 51.72K |
| Dollar Volume | 359.03M |
| Avg. Volume | 7.63M |
| Avg. Weekly Volume | 7.73M |
| Avg. Monthly Volume | 7.31M |
| Avg. Quarterly Volume | 7.83M |
AstraZeneca PLC (NYSE: AZN) stock closed at 64.49 per share at the end of the most recent trading day (a 2.14% change compared to the prior day closing price) with a volume of 5.58M shares and market capitalization of 199.85B. Is a component of NASDAQ 100 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 76100 people. AstraZeneca PLC CEO is Pascal Soriot.
The one-year performance of AstraZeneca PLC stock is 14.36%, while year-to-date (YTD) performance is 10.71%. AZN stock has a five-year performance of 88.73%. Its 52-week range is between 53.63 and 71.7, which gives AZN stock a 52-week price range ratio of 60.10%
AstraZeneca PLC currently has a PE ratio of -185.70, a price-to-book (PB) ratio of 5.38, a price-to-sale (PS) ratio of 5.28, a price to cashflow ratio of 25.90, a PEG ratio of 2.32, a ROA of -1.32%, a ROC of -0.09% and a ROE of -4.25%. The company’s profit margin is -2.48%, its EBITDA margin is 16.90%, and its revenue ttm is $37.87 Billion , which makes it $12.22 revenue per share.
Of the last four earnings reports from AstraZeneca PLC, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.84 for the next earnings report. AstraZeneca PLC’s next earnings report date is -.
The consensus rating of Wall Street analysts for AstraZeneca PLC is Strong Buy (1.4), with a target price of $74.25, which is +15.13% compared to the current price. The earnings rating for AstraZeneca PLC stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AstraZeneca PLC has a dividend yield of 2.99% with a dividend per share of $1.93 and a payout ratio of 93.00%.
AstraZeneca PLC has a Neutral technical analysis rating based on Technical Indicators (ADX : 8.92, ATR14 : 1.57, CCI20 : -44.54, Chaikin Money Flow : 0.03, MACD : -0.88, Money Flow Index : 48.96, ROC : -4.06, RSI : 47.96, STOCH (14,3) : 55.63, STOCH RSI : 1.00, UO : 54.61, Williams %R : -44.37), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AstraZeneca PLC in the last 12-months were:
AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
CEO: Pascal Soriot
Telephone: +44 2037495000
Address: 1 Francis Crick Avenue, Cambridge CB2 0AA, , GB
Number of employees: 76 100
TipRanks News for AZN
Wed, 04 May 2022 12:41 GMT AstraZeneca (AZN) Receives a Buy from SVB Securities
- TipRanks. All rights reserved.Sat, 30 Apr 2022 03:49 GMT AstraZeneca (AZN) Receives a Buy from Leerink Partners
- TipRanks. All rights reserved.Mon, 14 Mar 2022 12:40 GMT FDA Approves AstraZeneca and Mercks LYNPARZA
- TipRanks. All rights reserved.Thu, 03 Mar 2022 07:56 GMT AstraZeneca Acquires Neurimmunes Heart Failure Drug Candidate
- TipRanks. All rights reserved.Tue, 15 Feb 2022 14:35 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: AstraZeneca (AZN), Bruker (BRKR) and Neurocrine (NBIX)
- TipRanks. All rights reserved.Sun, 13 Feb 2022 14:46 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), AstraZeneca (AZN) and Dexcom (DXCM)
- TipRanks. All rights reserved.Thu, 10 Feb 2022 12:45 GMT AstraZenecas Q4 Results Outperform Shares Rise Pre-Market
- TipRanks. All rights reserved.Tue, 25 Jan 2022 10:27 GMT AstraZeneca Announces Orphan Drug Designation for Eplontersen in the U.S.
- TipRanks. All rights reserved.Mon, 03 Jan 2022 17:15 GMT AstraZeneca: Strong Growth, Balanced Pipeline, Rich Valuation
- TipRanks. All rights reserved.
